As up to 6% of stroke patients treated with tPA develop hemorrhages due to blood–brain barrier breakdown, microvascular damage and non-thrombolytic actions of tPA, the very real risk for intracranial catastrophe makes tPA an imperfect drug [27]. This evidence concerns the gene PLAT and Stroke.